Abstract 52P
Background
Post mastectomy adjuvant radiotherapy (RT) is a critical part in management of breast cancers. Left sided breast cancer cases are at higher risk of developing radiation induced cardiac morbidities. Increased radiation dose to the heart and lung may cause non-breast cancer related mortality and reduce the survival benefits from breast cancer RT. We designed a prospective clinical trial to examine the impact of CPAP on heart and lung during left sided post mastectomy radiotherapy.
Methods
24 left sided post mastectomy patients, after prior consent were included in this study. All patients were simulated in free breathing technique, followed by using CPAP (target pressure 10 to 15 cm of H20). Contouring was done using RTOG guideline. Heart and lung volumes were noted. IMRT virtual plans for both of these techniques were made for all patients using Monaco 5.51.10 software. Mean heart dose, Heart V25, Ipsilateral Lung mean dose, V5, V10, V20 were measured. Mean ± Std values were assessed using Students’ t-test.
Results
Compared to FB, CPAP showed significant difference. Mean heart distance from sternal notch was 6.2 cm and 7.2 cm ;p Value: 0.032 and Mean heart volumes were 354cc and 387cc in the CPAP and FB arms respectively;pValue: 0.665 . Mean left lung volumes were 1281 cc and 1398 cc respectively ;pValue 0.038 favouring CPAP arm. Similarly mean right lung volume of 1552 cc was significantly higher in CPAP arm compared to 1178 cc in FB arm (pValue : 0.041). Heart Dmean was found to be statistically better in CPAP arm (2.5 Gy) compared to FB arm (3.4 Gy) (p Value 0.020). Average V25 of heart was significantly superior in CPAP arm compared to FB arm (0.23% and 2.24% respectively,p Value 0.035). Heart Dmean was 3.1 Gy in CPAP arm compared to 3.7 Gy in FB arm ,pValue: 0.677. Similar result was found for heart V25. CPAP and FB Ipsilateral lung mean dose (6.69Gy and 6.32Gy, pValue: 0.62), Lung V5 (29% and 27.3%, p Value: 0.77), Lung V10 (16.3% and 16.4%, pValue: 0.78), Lung V20 (11.2% and 11.89%, p value 0.22) didn’t show statistical difference.
Conclusions
CPAP is an excellent tool for cardiac sparing in left sided post mastectomy breast cancer cases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract